AMGN vs. JNJ: Amgen vs. Johnson & Johnson Stock Comparison
How do Amgen (AMGN) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Amgen (AMGN) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while JNJ is classified in Pharmaceuticals.
| Profile Item | AMGN | JNJ |
|---|---|---|
| Name | Amgen Inc. | Johnson & Johnson |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 236.38 billion USD | 663.28 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 17, 1983 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Total Return (1Y) | 60.43% | 57.44% |
| Total Return (3Y, Annualized) | 23.06% | 23.15% |
| Total Return (5Y, Annualized) | 17.68% | 12.57% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Volatility (1Y, Annualized) | 27.61% | 19.01% |
| Beta (5Y) | 0.41 | 0.21 |
| Max Drawdown (5Y) | -24.86% | -18.41% |
| Avg. Volume (3M) | 2.67M | 7.79M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Sharpe Ratio (1Y) | 2.04 | 2.80 |
| Sortino Ratio (1Y) | 3.64 | 4.59 |
Profitability
ROE (TTM)
Both Amgen (AMGN) at 91.47% and Johnson & Johnson (JNJ) at 25.74% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
91.47%
- Max
- 102.29%
- AMGN
- 91.47%
- Q3
- 3.16%
- Median
- -32.34%
- Q1
- -64.79%
- Min
- -157.61%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.74%
- Max
- 102.29%
- JNJ
- 25.74%
- Q3
- 3.16%
- Median
- -32.34%
- Q1
- -64.79%
- Min
- -157.61%
Net Margin (TTM)
Both Amgen (AMGN) at 22.95% and Johnson & Johnson (JNJ) at 21.48% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.95%
- AMGN
- 22.95%
- Max
- 12.02%
- Q3
- 2.44%
- Median
- 0.00%
- Q1
- -4.89%
- Min
- -13.51%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.48%
- JNJ
- 21.48%
- Max
- 12.02%
- Q3
- 2.44%
- Median
- 0.00%
- Q1
- -4.89%
- Min
- -13.51%
Operating Margin (TTM)
Both Amgen (AMGN) at 35.55% and Johnson & Johnson (JNJ) at 29.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.55%
- Max
- 76.04%
- AMGN
- 35.55%
- Q3
- 10.45%
- Median
- 0.00%
- Q1
- -120.32%
- Min
- -308.66%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.19%
- Max
- 76.04%
- JNJ
- 29.19%
- Q3
- 10.45%
- Median
- 0.00%
- Q1
- -120.32%
- Min
- -308.66%
Profitability Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| ROE (TTM) | 91.47% | 25.74% |
| ROA (TTM) | 8.67% | 8.60% |
| Net Margin (TTM) | 22.95% | 21.48% |
| Operating Margin (TTM) | 35.55% | 29.19% |
| Gross Margin (TTM) | 71.89% | 68.14% |
Growth
Revenue Growth
Both Amgen (AMGN) at 9.95% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Amgen (AMGN) at 88.23% and Johnson & Johnson (JNJ) at 90.50% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.
Growth Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Revenue Growth (YoY) | 9.95% | 6.05% |
| Revenue Growth (3Y CAGR) | 11.77% | 5.60% |
| EPS Growth (YoY) | 88.23% | 90.50% |
| EPS Growth (3Y CAGR) | 5.52% | 17.90% |
Financial Strength
Current Ratio (MRQ)
Both Amgen (AMGN) at 1.37 and Johnson & Johnson (JNJ) at 1.09 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.37
- Max
- 26.10
- Q3
- 12.34
- Median
- 5.72
- Q1
- 2.80
- AMGN
- 1.37
- Min
- 0.10
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.09
- Max
- 26.10
- Q3
- 12.34
- Median
- 5.72
- Q1
- 2.80
- JNJ
- 1.09
- Min
- 0.10
Debt / Equity (MRQ)
Johnson & Johnson (JNJ) at 0.58 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 4.90 sits above its benchmark range, pointing to a heavier debt load relative to equity.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.90
- AMGN
- 4.90
- Max
- 1.56
- Q3
- 0.64
- Median
- 0.14
- Q1
- 0.02
- Min
- 0.00
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.58
- Max
- 1.56
- Q3
- 0.64
- JNJ
- 0.58
- Median
- 0.14
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Current Ratio (MRQ) | 1.37 | 1.09 |
| Debt / Equity (MRQ) | 4.90 | 0.58 |
| Net Debt / EBITDA | 2.51 | 0.81 |
Dividends
Dividend Yield (TTM)
Both Amgen (AMGN) at 2.21% and Johnson & Johnson (JNJ) at 1.88% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21%
- AMGN
- 2.21%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88%
- JNJ
- 1.88%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Amgen (AMGN) at 60.87% and Johnson & Johnson (JNJ) at 60.79% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.87%
- AMGN
- 60.87%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.79%
- JNJ
- 60.79%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Dividend Yield (TTM) | 2.21% | 1.88% |
| Dividend Payout Ratio (TTM) | 60.87% | 60.79% |
Valuation
P/E Ratio (TTM)
Both Amgen (AMGN) at 27.17 and Johnson & Johnson (JNJ) at 31.97 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.17
- Max
- 83.73
- Q3
- 44.68
- Median
- 28.50
- AMGN
- 27.17
- Q1
- 15.51
- Min
- 0.14
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.97
- Max
- 83.73
- Q3
- 44.68
- JNJ
- 31.97
- Median
- 28.50
- Q1
- 15.51
- Min
- 0.14
P/S Ratio (TTM)
On P/S ratio, both Amgen (AMGN) at 6.21 and Johnson & Johnson (JNJ) at 6.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.21
- Max
- 65.27
- Q3
- 29.50
- Median
- 7.31
- AMGN
- 6.21
- Q1
- 3.49
- Min
- 0.01
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.77
- Max
- 65.27
- Q3
- 29.50
- Median
- 7.31
- JNJ
- 6.77
- Q1
- 3.49
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Johnson & Johnson (JNJ) at 7.80 sits in the upper P/B ratio quartile, and Amgen (AMGN) at 20.22 prices even higher, above its industry range.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.22
- AMGN
- 20.22
- Max
- 15.46
- Q3
- 7.32
- Median
- 4.02
- Q1
- 1.90
- Min
- -5.81
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.80
- Max
- 15.46
- JNJ
- 7.80
- Q3
- 7.32
- Median
- 4.02
- Q1
- 1.90
- Min
- -5.81
Valuation Metrics
| Metric | AMGN | JNJ |
|---|---|---|
| P/E Ratio (TTM) | 27.17 | 31.97 |
| P/S Ratio (TTM) | 6.21 | 6.77 |
| P/B Ratio (MRQ) | 20.22 | 7.80 |
| Free Cash Flow Yield (TTM) | 3.66% | 2.55% |